ChemicalBook > Product Catalog >API >Antineoplastic agents >Tinib Antineoplastic drugs >Dasatinib

Dasatinib

Dasatinib Suppliers list
Company Name:Nanjing EnMing Pharmaceutical Technology Co., Ltd.  Gold
Tel:025-58894663 13305188663
Email:njempt@163.com
Company Name:Nanjing First Pharmaceutical Co., Ltd.  Gold
Tel:+86-25-83172655 /13776562784
Email:sales@njfirstpharm.com
Company Name:Guangzhou Isun Pharmaceutical Co., Ltd  Gold
Tel:020-39119399 18927568969
Email:isunpharm@qq.com, isunpharm@hotmail.com
Company Name:Jinan Kaypharm Chemical Co.,Ltd.  Gold
Tel:0531-86986780,13153183025
Email:sales@kaypharm.cn
Company Name:Yangzhou QinYuan Pharmaceutical Co., Ltd.  Gold
Tel:0514-80939770
Email:yzqychem@126.com
Dasatinib Basic information
Leukemia drug Chemical properties Uses
Product Name:Dasatinib
Synonyms:Dasatinib(BMS-354825);BMS-354825;N-[2-Chloro-6-methylphenyl]-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide;5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-;Dasatinib;N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide;N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide;2-{6-[4-(2-HYDROXY-ETHYL)-PIPERAZIN-1-YL]-2-METHYL-PYRIMIDIN-4-YLAMINO}-THIAZOLE-5-CARBOXYLIC ACID (2-CHLORO-6-METHYL-PHENYL)-AMIDE
CAS:302962-49-8
MF:C22H28ClN7O3S
MW:488.01
EINECS:
Product Categories:Intermediates & Fine Chemicals;Pharmaceuticals;Tyrosine Kinase Inhibitors;Pharmaceutical intermediate;Inhibitor;Sprycel;Anti-cancer&immunity;Inhibitors
Mol File:302962-49-8.mol
Dasatinib Structure
Dasatinib Chemical Properties
mp 275-286°C
storage temp. -20°C Freezer
CAS DataBase Reference302962-49-8(CAS DataBase Reference)
Safety Information
MSDS Information
Dasatinib Usage And Synthesis
Leukemia drugDasatinib is an oral potent oncogenic kinase inhibitor, which can block signal of cancer cell replication acceleration , in May 2009, the US Food and Drug Administration (FDA) formally approved the sale of dasatinib , It has been clinically used for the treatment of various chronic myeloid leukemia (CML), including treatment of chronic myeloid leukemia which is resistant or intolerant to the treating programs including imatinib mesylate., Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) and the treatment of patients with solid tumors.
October 28, 2010 ,the FDA approved dasatinib (Sprycel) of the new indication which is used for the treatment of the rare leukemia first diagnosed Philadelphia chromosome-positive called chronic myeloid leukemia (Ph + CP-CML) . The disease is a blood and bone marrow disease associated with genetic abnormality .
An open-label randomized clinical trial conducted in patients with CP-CML evaluated the safety and efficacy of dasatinib . Common side effects include decreased activity of the bone marrow caused by red blood cells, white blood cells and platelets decreased (myelosuppression), fluid retention, diarrhea, headache, musculoskeletal pain, and rash.
October 11, 2011, the US Food and Drug Administration (FDA) said the leukemia drug dasatinib (Sprycel, Bristol-Myers Squibb Company) might increase pulmonary arterial hypertension (PAH) risk. Pulmonary hypertension is a rare but serious disease that can lead to the condition that heart pumping blood to the lungs becomes more difficult by raising the pressure . PAH symptoms include shortness of breath, fatigue, swelling of the legs and ankles, clinicians must differentiate these symptoms from other similar symptoms.
Since 2006 Dasatinib was approved in the US market ,there had been 12 associated pulmonary hypertension events ,pulmonary hypertension symptoms included shortness of breath, fatigue, hypoxia and fluid retention, patients then were confirmed pulmonary hypertension by the results of right heart catheterization ,studies have shown that the biggest cause of the disease may come from patients taking dasatinib.
The above information is edited by the Chemicalbook of Tian Ye.
Chemical propertiesWhite solid
UsesSuitable for treatment of chronic myeloid leukemia which is resistant or intolerant to the treating programs including imatinib mesylate.
Chemical PropertiesPale-Yellow Solid
UsageA new, oral, small-molecule Tyrosine Kinase Inhibitor (TKI) for the treatment of CML. Antineoplastic
UsageDasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
Dasatinib Preparation Products And Raw materials
Tag:Dasatinib(302962-49-8) Related Product Information
Dasatinib Metabolite M4-d8,N-Deshydroxyethyl Dasatinib-d8 Dasatinib Carboxylic Acid Dasatinib-d8 N-Oxide Dasatinib N-Oxide 2-(METHYLSULFONYL)ETHANOL Gefitinib Lapatinib Sunitinib Chloroacetic acid Difluorochloromethane Imatinib Piperazine ferulate N-Aminoethylpiperazine 2-Amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide 2-[4-(6-AMINO-2-METHYLPYRIMIDIN-4-YL)PIPERAZIN-1-YL]ETHANOL 4-AMINO-6-(4-METHYL-1-PIPERAZINYL)PYRIMIDINE Dasatinib Epichlorohydrin